Company news
Neurizon Therapeutics Limited news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Receipt of 25kg of GMP-Grade Monepantel from Elanco
May 8, 2019
Phase I Canine Repeat Dose MPL Demonstrates High Performance
May 5, 2019
PharmAust Receives $672,250 R&D Tax Incentive Refund
April 29, 2019
Shortfall Placement Oversubscribed
April 11, 2019
Phase I Monepantel Tablets Demonstrate High Safety
March 27, 2019
PharmAust Raises $1.3m in Rights Issue
March 21, 2019
MPL Tablets Demonstrate Positive Performance in Phase 1
March 13, 2019
PharmAust Rights Issue Reaches Minimum Subscription
March 12, 2019
Appendix 4D & Financial Report
February 28, 2019
Offer Document - Rights Issue
February 25, 2019
Phase I Dog Trial with New Monepantel Tablets Commences
February 19, 2019
Non-Renounceable Rights Offer
February 17, 2019
PAA Completes Successful Taste Mask Testing of New Tablet
February 10, 2019
PharmAust Signs Agreement for US Phase I Trials in Dogs
February 6, 2019
PharmAust Completes Scaled Manufacture of Monepantel Tablets
February 6, 2019
PharmAust Appendix 4C and Shareholders Update
January 31, 2019
PharmAust and Elanco Execute Data Sharing Agreement
January 28, 2019
Optimisation of Monepantel Uptake
January 20, 2019
Monepantel Principal Metabolite Shows Anti-Cancer Activity
January 13, 2019
PharmAust Develops Method for MPL/Analogue Manufacture
December 2, 2018
GMP Tablet Manufacture Commences for Canine Clinical Trials
November 12, 2018
Appendix 4C & Company Update - Sep 2018
October 31, 2018
PharmAust Develops GMP Method for Monepantel Analogues
October 28, 2018
PharmAust Progresses Monepantel Tablet Program for Cancer
October 14, 2018
Olivia Newton-John Cancer Reseach Institute collaboration
September 10, 2018
Reformulation of MPL into tablet form for upcoming trials
September 3, 2018
Appendix 4C & Company Update - June 18
July 31, 2018
Epichem gains prestigious international ISO accreditation
July 1, 2018
Epichem Awarded Major US Drug Discovery Contract Extension
June 6, 2018
MPL successfully reformulated for canine clinical trials
May 27, 2018
Chief Executive Officer resigns
May 21, 2018
Appendix 4C & Company Update
April 30, 2018
PharmAust enters option to license agreement with Elanco
April 18, 2018
Appendix 4D and Half Yearly Report & Accounts
February 28, 2018
PharmAust receives $354k R&D Tax Incentive Refund
February 27, 2018
Appendix 4C - Quarterly Report & Shareholders Update
January 30, 2018
Monepantel reformulation successfully improves dose & taste
January 29, 2018
Epichem Awarded One Year Contract Extension from DNDi
January 17, 2018
Phase II Dog Lymphoma Trial Confirms MPL Clinical Benefit
December 12, 2017
PharmAust Raises $1.873m via an Oversubscribed Placement
December 5, 2017
New MPL analogues show greater anti-cancer activity
November 22, 2017
New drugs patented for cancer in USA
November 15, 2017
Epichem Update - progress on milestones and revenue targets
October 31, 2017
Appendix 4C - Quarterly Report & Brief Company Update
October 26, 2017
Monepantel reformulation project continues to progress
October 16, 2017
New patent secured in US for non-cancer applications
October 9, 2017
Reformulation project achieves first milestones and on-track
September 19, 2017
PharmAust secures core Europe patent
September 11, 2017
PharmAust & Nihon Nohyaku Japan Enter Assignment Agreement
September 3, 2017
Appendix 4E & Full Year Statutory Accounts 2017
August 31, 2017
Decks
The 5 newest of 37 decks. Every deck is listed under its year.
- Investor Presentation (November 2026)
Investor deck · 15 slides · Nov 5, 2026
- Investor Presentation (October 2026)
Investor deck · 33 slides · Oct 7, 2026
- Investor Presentation (July 2026)
Investor deck · 23 slides · Jul 29, 2026
- Corporate Update (May 2026)
Corporate update · 13 slides · May 28, 2026
- 15th Annual Australian Microcap Investment Conference 2026
Conference · 27 slides · May 11, 2026